S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
NASDAQ:NKTR

Nektar Therapeutics (NKTR) Stock Forecast, Price & News

$0.58
-0.04 (-6.45%)
(As of 05/31/2023 ET)
Compare
Today's Range
$0.58
$0.65
50-Day Range
$0.62
$1.03
52-Week Range
$0.58
$5.18
Volume
7.06 million shs
Average Volume
3.84 million shs
Market Capitalization
$109.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.40

Nektar Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
1.60 Rating Score
Upside/​Downside
313.7% Upside
$2.40 Price Target
Short Interest
Bearish
5.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
-0.01mentions of Nektar Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$21,709 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.15) to ($0.90) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

565th out of 1,006 stocks

Pharmaceutical Preparations Industry

277th out of 492 stocks


NKTR stock logo

About Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Stock News Headlines

Howard Robin seeks another turnaround at Nektar
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Jefferies upgrades Nektar Therapeutics (NKTR) to a Hold
Nektar Therapeutics Reports First Quarter 2023 Financial Results
Nektar Therapeutics Q1 Loss increases, misses estimates
Brokerages Set Nektar Therapeutics (NASDAQ:NKTR) PT at $3.08
Goldman Sachs Remains a Sell on Nektar Therapeutics (NKTR)
Mizuho Securities Remains a Hold on Nektar Therapeutics (NKTR)
See More Headlines
Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Company Calendar

Last Earnings
2/28/2023
Today
5/31/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:NKTR
CUSIP
64026810
Employees
740
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$2.40
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+292.2%
Consensus Rating
Hold
Rating Score (0-4)
1.60
Research Coverage
5 Analysts

Profitability

Net Income
$-368,200,000.00
Net Margins
-467.00%
Pretax Margin
-463.59%

Debt

Sales & Book Value

Annual Sales
$92.06 million
Book Value
$1.27 per share

Miscellaneous

Free Float
182,839,000
Market Cap
$115.80 million
Optionable
Optionable
Beta
1.09

Social Links


Key Executives

  • Howard W. RobinHoward W. Robin
    President, Chief Executive Officer & Director
  • Sandra A. Gardiner
    Chief Financial & Accounting Officer
  • Mary Tagliaferri
    Chief Medical Officer
  • Jonathan ZalevskyJonathan Zalevsky
    Chief Research & Development Officer
  • Mark A. Wilson
    Secretary, Chief Legal Officer & Senior VP













NKTR Stock - Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 2 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View NKTR analyst ratings
or view top-rated stocks.

What is Nektar Therapeutics' stock price forecast for 2023?

5 Wall Street research analysts have issued 12-month target prices for Nektar Therapeutics' stock. Their NKTR share price forecasts range from $1.00 to $3.00. On average, they expect the company's share price to reach $2.40 in the next year. This suggests a possible upside of 292.2% from the stock's current price.
View analysts price targets for NKTR
or view top-rated stocks among Wall Street analysts.

How have NKTR shares performed in 2023?

Nektar Therapeutics' stock was trading at $2.26 at the start of the year. Since then, NKTR shares have decreased by 72.9% and is now trading at $0.6119.
View the best growth stocks for 2023 here
.

When is Nektar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our NKTR earnings forecast
.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.11. The biopharmaceutical company earned $22.02 million during the quarter, compared to the consensus estimate of $22.21 million. Nektar Therapeutics had a negative net margin of 467.00% and a negative trailing twelve-month return on equity of 84.36%. The company's revenue was down 11.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.79) earnings per share.

What ETFs hold Nektar Therapeutics' stock?

ETFs with the largest weight of Nektar Therapeutics (NASDAQ:NKTR) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Invesco Nasdaq Future Gen 200 ETF (QQQS) and Inspire Small/Mid Cap ETF (ISMD) and

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (18.79%), State Street Corp (3.69%), Pictet Asset Management SA (1.97%), Geode Capital Management LLC (1.86%), Renaissance Technologies LLC (1.59%) and AQR Capital Management LLC (1.45%). Insiders that own company stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, R Scott Greer and Robert Chess.
View institutional ownership trends
.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $0.61.

How much money does Nektar Therapeutics make?

Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $115.80 million and generates $92.06 million in revenue each year. The biopharmaceutical company earns $-368,200,000.00 in net income (profit) each year or ($2.21) on an earnings per share basis.

How many employees does Nektar Therapeutics have?

The company employs 740 workers across the globe.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300.

This page (NASDAQ:NKTR) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -